GMJ Medicine
eISSN : 2626-3041
Embase
Biosis Previews
description
Volume 1, Issue 3 (2022)
GMJM 2022, 1(3): 97-100 |
Back to browse issues page
Article Type:
Subject:
History
Received: 2022/02/22 | Accepted: 2022/06/17 | Published: 2022/08/3
Received: 2022/02/22 | Accepted: 2022/06/17 | Published: 2022/08/3
How to cite this article
Mohammadipour Anvari H, Sadeghi S. Comparison of Ondansetron and Metoclopramide in Prevention of Nausea and Vomiting after Coronary Artery Bypass Graft Surgery. GMJM 2022; 1 (3) :97-100
URL: http://gmedicine.de/article-2-202-en.html
URL: http://gmedicine.de/article-2-202-en.html
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Rights and permissions
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Authors
H. Mohammadipour Anvari *1, S. Sadeghi1
1- Tuberculosis and Lung Disease Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
Abstract (776 Views)
Aims: The aim of this study was to determine the effect of ondansetron and metoclopramide on the prevention of PONV in high-risk patients. The reason for choosing these two drugs is that ondansetron is a drug that is widely used in the world today as a first-line drug in the prevention and treatment of PONV, and metoclopramide is a drug that is cheap and available as a common anti-emetic drug by surgeons PONV control is prescribed in Iran.
Materials & Methods: A total of 126 patients who were candidates for coronary artery bypass graft surgery during 2018 and 2019 were evaluated in this study. Intraoperative injection of metoclopramide or ondansetron was compared between all patients and the severity of postoperative nausea and vomiting was compared.
Findings: The rate of nausea in patients was about 67.5% with an average of 158.5 seconds of nausea in these patients each day and there was no significant difference between the two drug groups in terms of these two variables (p=0.342; p=0.900). The average rate of vomiting in patients was 19.8%, of which 52% had vomiting once and 48% had vomited more than once. There was a significant difference in the presence of vomiting in the two drug groups (p=0.044).
Conclusion: Metoclopramide and Ondansetron have the similar effects on nausea and vomiting after coronary artery bypass graft surgery.
Materials & Methods: A total of 126 patients who were candidates for coronary artery bypass graft surgery during 2018 and 2019 were evaluated in this study. Intraoperative injection of metoclopramide or ondansetron was compared between all patients and the severity of postoperative nausea and vomiting was compared.
Findings: The rate of nausea in patients was about 67.5% with an average of 158.5 seconds of nausea in these patients each day and there was no significant difference between the two drug groups in terms of these two variables (p=0.342; p=0.900). The average rate of vomiting in patients was 19.8%, of which 52% had vomiting once and 48% had vomited more than once. There was a significant difference in the presence of vomiting in the two drug groups (p=0.044).
Conclusion: Metoclopramide and Ondansetron have the similar effects on nausea and vomiting after coronary artery bypass graft surgery.
Keywords:
| | Full-Text (HTML) (28 Views)
References
1. Pitts SR. Neither ondansetron nor metoclopramide reduced nausea and vomiting in the emergency department. Ann Intern Med. 2014;161:JC3. [Link] [DOI:10.7326/0003-4819-161-12-201412160-02003]
2. Talebpour M, Ghiasnejad Omrani N, Imani F, Shariat Moharari R, Pourfakhr P, Khajavi MR. Comparison effect of promethazine/dexamethasone and metoclopramide /dexamethasone on postoperative nausea and vomiting after laparascopic gastric placation: a randomized clinical trial. Anesth Pain Med. 2017;7:e57810. [Link] [DOI:10.5812/aapm.57810]
3. Maitra S, Som A, Baidya DK, Bhattacharjee S. Comparison of ondansetron and dexamethasone for prophylaxis of postoperative nausea and vomiting in patients undergoing laparoscopic surgeries: A meta-analysis of randomized controlled trials. Anesthesiol Res Pract. 2016;2016:7089454. [Link] [DOI:10.1155/2016/7089454]
4. Dalhat S, Mohammad A. Comparison of ondansetron and metoclopramide for the prevention of post-operative nausea and vomiting in day-case gynaecological laparoscopic surgeries. Niger J Basic Clin Sci. 2018;15(1):24-8. [Link] [DOI:10.4103/njbcs.njbcs_15_17]
5. Reza A, Riahi E, Daneshi A, Golchini E. The incidence of traumatic brain injury in Tehran, Iran. Brain Inj. 2018;32(4):487-92. [Link] [DOI:10.1080/02699052.2018.1429658]
6. Balakrishnan B, Rus RM, Chan KH, Martin AG, Awang MS. Prevalence of postconcussion syndrome after mild traumatic brain injury in young adults from a single neurosurgical center in east coast of Malaysia. Asian J Neurosurg. 2019:14(1):201-5. [Link] [DOI:10.4103/ajns.AJNS_49_18]
7. Bagheri-Hariri S, Bahreini M, Farshidmehr P, Barazandeh S, Babaniamansour S, Aliniagerdroudbari E, et al. The effect of extended-focused assessment with sonography in trauma results on clinical judgment accuracy of the physicians managing patients with blunt thoracoabdominal trauma. Arch Trauma Res. 2019;8(4):207-13. [Link] [DOI:10.4103/atr.atr_57_19]
8. Farzaneh E, Fattahzadeh-Ardalani G, Abbasi V, Kahnamouei-aghdam F, Molaei B, Iziy E, et al. The epidemiology of hospital-referred head injury in Ardabil city. Emerg Med Int. 2017;2017:1439486. [Link] [DOI:10.1155/2017/1439486]
9. Gerritsen H, Samim M, Peters H, Schers H, van de Laar FA. Incidence, course and risk factors of head injury: A retrospective cohort study. BMJ Open. 2018;8(5):e020364. [Link] [DOI:10.1136/bmjopen-2017-020364]
10. Zamani M, Namdar B, Azizkhani R, Ahmadi O, Esmailian M. Comparing the antiemetic effects of ondansetron and metoclopramide in patients with minor head trauma. Emergency. 2015;3(4):137-40. [Link]
11. Hashimoto H, Abe M, Tokyama O, Mizutani H, Uchitomi Y, Yamaguchi T, et al. Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020:21(2):242-9. [Link] [DOI:10.1016/S1470-2045(19)30678-3]
12. Ithimakin S, Theeratrakul P, Laocharoenkiat A, Nimmannit A, Akewanlop C, Soparattanapaisarn N, et al. Randomized, double-blind, placebo-controlled study of aprepitant versus two dosages of olanzapine with ondansetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving high-emetogenic chemotherapy. Support Care Cancer. 2020;28:5335-42. [Link] [DOI:10.1007/s00520-020-05380-6]
13. Jeon SY, Han HS, Bae WK, Park MR, Shim H, Lee SC, et al. A randomized, double-blind, placebo-controlled study of the safety and efficacy of olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: results of the korean south west oncology group (KSWOG) study . Cancer Res Treat. 2019;51:90-7. [Link] [DOI:10.4143/crt.2017.577]
14. Mukhopadhyay S, Kwatra KPA, Badyal D. Role of olanzapine in chemotherapy-induced nausea and vomiting on platinum-based chemotherapy patients: A randomized controlled study. Support Care Cancer. 2017;25:145-54. [Link] [DOI:10.1007/s00520-016-3386-9]
15. Tienchaiananda P, Nipondhkit W, Maneenil K, Sa-Nguansai S, Payapwattanawong S, SLaohavinij S, et al. A randomized, double-blind, placebo-controlled study evaluating the efficacy of combination olanzapine, ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving doxorubicin plus cyclophosphamide. Ann Palliat Med. 2019;8:372-80. [Link] [DOI:10.21037/apm.2019.08.04]
16. Navari RM, Pywell CM, Le-Rademacher JG, White P,. Dodge AB, Albany C, et al. Olanzapine for the Treatment of Advanced Cancer-Related Chronic Nausea and/or Vomiting. JAMA Oncol. 2020;6:895-9. [Link] [DOI:10.1001/jamaoncol.2020.1052]
17. Kalakonda N, Maerevoet M, Cavallo F, Follows G, Goy A, Vermaat JS, et al. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial. Lancet Haematol. 2020;7:e511-e522. [Link] [DOI:10.1016/S2352-3026(20)30120-4]
18. Chari A, Vogl DT, Gavriatopoulou M, Nooka AK, Yee AJ, Huff CA, et al. Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. N Engl J Med. 2019;38(8):727-38. [Link] [DOI:10.1056/NEJMoa1903455]